Skip to main content
. 2022 Mar;43(3):455–461. doi: 10.3174/ajnr.A7433

FIG 1.

FIG 1.

The decrease at 24 months in the mean, median, and mode of ADC_total with treatment in a 6-year-old boy with a WHO grade I glioma with a BRAF aberration who responded to selumetinib. The initial transient increase in these metrics seen here was observed in 5 of the 8 responders in stratum 1 and is possibly linked to increased water mobility due to early cell death, followed by tissue consolidation later in treatment. Tx indicates treatment.